Condition
Berylliosis
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
1 treatments under study, led by Infliximab
Research Leaders
5 sponsors active, led by Centocor, Inc.
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Infliximab1
Active Sponsors
- Centocor, Inc.1
- National Heart, Lung, and Blood Institute (NHLBI)1
- Maier, Lisa, M.D.1
- National Jewish Health1
- National Center for Research Resources (NCRR)1
Top Investigators
National Jewish Health
National Jewish Health
Related Conditions
- Beryllium Disease1
- Sarcoidosis1